Tech Company Financing Transactions
Salubris Biotherapeutics Funding Round
Salubris Biotherapeutics, based in Gaithersburg, scored $32 million from Shenzhen Salubris Pharmaceuticals.
Transaction Overview
Company Name
Announced On
3/7/2022
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Undisclosed
Investors
Shenzhen Salubris Pharmaceuticals (Lead Investor)
Proceeds Purpose
Investment will be used to advance the current pipeline, including continuation of an ongoing Phase 1b clinical trial and initiation of two additional Phase 1b clinical trials in 2022, and to further expand the pipeline through R&D.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
45 West Watkins Mill Road Suite E
Gaithersburg, MD 20878
USA
Gaithersburg, MD 20878
USA
Phone
Undisclosed
Website
Email Address
Overview
Operator of an innovation-focused biotechnology company intended to develop transformative therapeutic molecules. The company's focus is on the development of novel antibody and protein-based therapeutics for the treatment of cancer and cardiovascular diseases, enabling patients with significant medical needs to lead a quality life.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sam Murphy
Chief Financial Officer
Stephen DiPalma
Vice President
Jinhua Feng
Browse more venture capital transactions:
Prev: 3/6/2022: V-Ensure Pharma Technologies venture capital transaction
Next: 3/7/2022: MindMaze venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. All VC database entries reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs